The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

[1]  L. Pickering,et al.  Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis , 2020, Journal of immunotherapy.

[2]  G. Hospers,et al.  Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy , 2020, Cancers.

[3]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[4]  D. Palma,et al.  The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  James E. Clune,et al.  Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma , 2019, Journal of Immunotherapy for Cancer.

[6]  R. Dummer,et al.  Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. , 2019 .

[7]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[8]  V. Servois,et al.  Novel patterns of response under immunotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Loi,et al.  Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses , 2018, Front. Immunol..

[10]  A. Bilchik,et al.  Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy , 2017, JAMA surgery.

[11]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[12]  J. F. De Los Santos,et al.  Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab , 2016, Journal of immunotherapy.

[13]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[14]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[15]  Charles Swanton,et al.  Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.

[16]  R. Emerson,et al.  Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes , 2014, Oncoimmunology.

[17]  V. Sondak,et al.  A phase 2 trial of complete resection for stage IV melanoma , 2011, Cancer.

[18]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.

[19]  W. Hohenberger,et al.  Surgical therapy for distant metastases of malignant melanoma , 2000, Cancer.